(HealthDay)—Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first “biosimilar” to the anemia
Continue reading »
mypharmacynews.com
Home »
(HealthDay)—Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first “biosimilar” to the anemia
Continue reading »